Conference Introduction
Immunity plays a key role in human health and disease. To follow the rapid advances in the field, the Fuzhou Conference entitled “Immunity in Health and Disease” will be held from November 14 to 17, 2017 in Fuzhou, China. The conference is divided into the following sessions including Innate immunity, Adaptive immunity, Infection, Inflammation and autoimmunity, and Cancer. The Conference will bring together international leading scientists to explore insights into immunity mechanisms related to the innate and acquired immune signaling and regulation in the pathogenic, preventive and therapeutic bases of various diseases including cancer, infectious diseases, autoimmune diseases, and neurodegenerative disorders, etc. The conference will start on Tuesday, November 15 at 8:30 a.m. and end in the evening of November 16. The detail information regarding the conference can be found at “http://fuzhou-conference.fjnu.edu.cn/”. The on-site registration and check-in will be open on November 14, 2017.
Sponsorship
Christopher Stolz1
Jules A. Hoffmann
2011 Nobel Laureate, Member of French Academy of Sciences, France
Christopher Stolz1
Tasuku Honjo
Kyoto University, Member of Japan Academy, Japan
Christopher Stolz1
Shizuo Akira
Osaka University, Member of Japan Academy, Japan
Christopher Stolz1
Xuetao Cao
Chinese Academy of Medical Sciences, Member of the CAE, China
Christopher Stolz1
Zhijian "James" Chen
The University of Texas, Southwestern Medical Center, Member of NAS, USA
Christopher Stolz1
Chen Dong
Tsinghua University,China
Christopher Stolz1
Fu Gao
Chinese Center For Disease Control And Prevention, Member of the CAS, China
Christopher Stolz1
Lieping Chen
Yale University, Co-Director of Cancer Immunology Program at Yale Cancer Center, USA
Christopher Stolz1
Jiahuai Han
Xiamen University, Member of Chinese Academy of Sciences
Christopher Stolz1
Tak Wah Mak
University of Toronto, Canada, Fellow of the Royal Society of London (UK)
Christopher Stolz1
Kenneth M. Murphy
Washington University, Member of the National Academy of Sciences of USA
Christopher Stolz1
Hai Qi
Tsinghua University, China
Christopher Stolz1
Feng Shao
National Institute of Biological Sciences, Member of CAS, China
Christopher Stolz1
Shu Hongbing
Wuhan University, Member of the Chinese Academy of Science
Christopher Stolz1
Louis Staudt
NIH, National Cancer Institute, Member of the National Academy of Sciences of USA
Christopher Stolz1
Zhigang Tian
University of Science and Technology of China
Christopher Stolz1
Li Wu
Tsinghua University, China
 Jules A. Hoffmann
Jules A. Hoffmann
2011 Nobel Laureate, Member of French Academy of Sciences, France
Dr. Jules A. Hoffmann won the 2011 Nobel Prize in Physiology or Medicine for "the discoveries concerning the activation of innate immunity". He currently holds a faculty position at the University of Strasbourg and is a research director and member of the board of administrators of the National Center of Scientific Research (CNRS) in Strasbourg, France. He was elected to the positions of Vice-President (2005-2006) and President (2007-2008) of the French Academy of Sciences. Hoffmann’s lab discovered the function of the fruit fly Toll gene in innate immunity. Toll-like receptors identify constituents of other organisms like fungi and bacteria, and trigger an immune response, explaining, for example, how septic shock can be triggered by bacterial remains.
Tasuku Honjo
Tasuku Honjo
Kyoto University, Member of Japan Academy, Japan
Dr. Tasuku Honjo is a Japanese immunologist at Kyoto University and is best known for his discovery of Programmed Cell Death Protein 1 (PD-1), a target of most effective cancer immunotherapy to-date. Dr. Honjo is a member of Japan Academy and a foreign member of National Academy of Sciences, USA. He is also known for molecular identification of cytokines: IL-4 and IL-5, as well as the discovery of Activation-Induced Cytidine Deaminase (AID) that is essential for class switch recombination and somatic hypermutation. Honjo has established the basic conceptual framework of class switch recombination and presented a model explaining antibody gene rearrangement in class switch.
Shizuo Akira
Shizuo Akira
Osaka University, Member of Japan Academy, Japan
Dr. Shizuo Akira is a member of Japan Academy of Sciences and a Foreign member of National Academy and a professor at the Osaka University, Japan. He has made ground-breaking discoveries in the field of innate host defense mechanisms. He discovered a collection of molecules of microbial origin, and RNA helicases, RIG-I (retinoic-acid-inducible protein I) and MDA5 (melanoma differentiation-associated protein 5) which belong to the pattern recognition receptors and detect intruding pathogens and initiates antimicrobial responses in the host. He is the recipient of numerous international awards, including the Gairdner Foundation International Award (2011), Robert Koch Prize, the Milstein Award (2007), and the William B. Coley Award.
Xuetao Cao
Xuetao Cao
Chinese Academy of Medical Sciences, Member of the CAE, China
Dr. Xuetao Cao is the current president of Chinese Academy of Medical Sciences and Peking Union Medical College. Dr. Cao was elected to the Chinese Academy of Engineering in 2005, German Academy of Sciences in 2013, French Academy of Medicine in 2014, EMBO in 2015 and UK Academy of Medicine in 2016. He is currently a professor and director of the Center for Immunotherapy at Chinese Academy of Medical Sciences (Beijing, China). He is the Founder Director of the Institute of Immunology at Zhejiang University since 2000. He has also been Professor and Director of the National Key Laboratory of Medical Immunology since 2006. He was President of Chinese Society for Immunology (2006.10-2014.10), President of Federation of Immunological Societies in Asia and Oceania FIMSA (2012.5-2015.6) and President of Global Alliance for Chronic Diseases GACD (2013.12-2015.12). He is currently the Secretary General of Chinese Society for Immunology (2014.10- ), and Secretary General of FIMSA (2016.6- ). His research focuses on the understanding of innate signaling in immunity and inflammation, identification of cell subsets and new molecules in dendritic cell (DC)-initiated immune response and cancer immunotherapy. He has identified several important regulators of innate immune response and inflammation, characterized cell subsets with regulatory function involved in immunity and cancer. He is Founder and Editor-in-Chief of Chinese Journal of Cancer Biotherapy, and Editor-in-Chief of Cellular and Molecular Immunology. He has won numerous awards in recognition of his scientific achievements and dedication to public services and China's medical research and education.
Zhijian
Zhijian "James" Chen
The University of Texas, Southwestern Medical Center, Member of NAS, USA
Dr. Zhijian "James" Chen is a Member of National Academy of Sciences, an Investigator of Howard Hughes Medical Institute. He currently holds George L. MacGregor Distinguished Chair in Biomedical Science and is a Professor at University of Texas Southwestern Medical Center. He is best known for using classical biochemistry to discover new pathways and mechanisms in innate immunity and cell signaling. His scientific contributions include the discovery of a proteasome-independent role of ubiquitin in protein kinase activation, the discovery of MAVS (Mitochondrial Anti-Viral Signaling protein) and the role of mitochondria in antiviral innate immune responses, and the discoveries of the cytosolic DNA sensor, Cyclic GMP-AMP synthase (cGAS; cGAMP synthase), and a new second messenger, Cyclic guanosine monophosphate–adenosine monophosphate (cyclic GMP-AMP, cGAMP). He has won numerous distinctions for his scientific contributions including the Norman Hackerman Award in Chemical Research, the Edith and Peter O’Donnell Award in Science, and the National Academy of Sciences Award in Molecular Biology.
Chen Dong
Chen Dong
Tsinghua University,China
Dr. Chen Dong is a Professor and Dean of School of Medicine, and a Professor of School of Life Sciences, Tsinghua University. His research focuses on the regulation of cytokines including IL-17, IL-21 and BCL6 in T helper development and cell function related to inflammation and autoimmune disease.
Fu Gao
Fu Gao
Chinese Center For Disease Control And Prevention, Member of the CAS, China
Dr. Fu Gao is a member of Chinese Academy of Sciences and the Director and Professor, CAS Key Laboratory of Pathogenic Microbiology Immunology, Institute of Microbiology and. Dr. Gao’s research focuses on protein-protein interactions related to molecular virology and molecular immunology, and molecular epidemiology and molecular phylogeny of zoonotic pathogens, including avian influenza virus, HIV, SARS coronavirus, paramyxovirus. Dr. Gao also works on the molecular basis of T cell (the second arm of the immune system after the B-cell antibody system) antigen recognition.
Lieping Chen
Lieping Chen
Yale University, Co-Director of Cancer Immunology Program at Yale Cancer Center, USA
Dr. Lieping Chen is a United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology) at Yale University. He is Co-Director of Cancer Immunology Program at Yale Cancer Center. Dr. Lieping Chen studies lymphocyte costimulation and coinhibition, and their application in treating human diseases including cancer and autoimmune diseases. Dr. Chen pioneered the first proof-of-concept study showing that manipulation of the B7-CD28/CTLA-4 family molecules could be used for cancer immunotherapy by introducing B7-1 into tumor cells to enhance tumor immunity in 1992. He co-discovered the PD-1/PD-L1 pathway and elucidated its functions including discovery of B7-H1 (PD-L1) molecule. These studies have singularly established the PD-1/PD-L1 pathway as target for cancer immunotherapy and diagnosis, and led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. He also discovered multiple costimulatory and coinhibitory pathways, their immunological functions and applications in human disease treatment including 4-1BB, ICOS/B7-H2, B7-H3, B7-H4, B7-H5/CD28H, PD-1H, LIGHT/HVEM, TROY, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM. These discoveries have led to the development of therapeutic agonist anti-4-1BB antibody (cancer), anti-B7-H3 antibody (cancer) anti-B7-H4 antibody (cancer) and B7-H4Ig fusion protein (autoimmune diseases) which are currently in clinical trials. He has received numerous international awards including the William B. Coley Award (2014) and the AAI-Steinman Award (2016).
Jiahuai Han
Jiahuai Han
Xiamen University, Member of Chinese Academy of Sciences
Dr. Jiahuai Han is a member of Chinese Academy of Sciences, Vice President and Professor of Xiamen University. He is a distinguished Professor of Chinese “Thousand Talents Program” and Chinese “Chang Jiang Scholars Program”. Dr. Jiahuai Han is best known for the discovery of the p38 signaling pathway. This pathway plays important roles in many biological processes including cell cycle regulation, cell proliferation, cell differentiation and senescence, as well as immune reactions, development and tumorigenesis. Dr Han`s another major contribution is the dicovery of RIP3-dependent necrosis.
Tak Wah Mak
Tak Wah Mak
University of Toronto, Canada, Fellow of the Royal Society of London (UK)
Dr. Tak Wah Mak is a Professor at the Campbell Family Institute for Breast Cancer Research, and a professor of Ontario Cancer Institute, Princess Margaret Hospital, University of Toronto. He is an Officer of the Order of Canada and has been elected a Foreign Associate of the National Academy of Sciences (USA) as well as a Fellow of the Royal Society of London (UK.) He is widely known for his discovery of the T-cell receptor and pioneering work in the genetics of immunology. He holds Honorary Doctoral Degrees from numerous universities in North America and Europe. He has won international recognition in the forms of the Emil von Behring Prize, the King Faisal Prize for Medicine, theGairdner Foundation International Award, the Sloan Prize of the General Motors Cancer Foundation, the Paul Ehrlich and Ludwig Darmstaedter Prize and the Novartis Prize in Immunology.
Kenneth M. Murphy
Kenneth M. Murphy
Washington University, Member of the National Academy of Sciences of USA
Dr. Kenneth M. Murphy is a Howard Hughes Medical Institute Investigator and Eugene Opie First Centennial Professor of Pathology & Immunology at the Washington University School of Medicine. He was elected to the National Academy of Sciences of USA in 2016. Dr. Murphy is best known for his research into the development of T cells to fight infections. His early discovery that dendritic cells and macrophages determined the direction of T cell differentiation, by their production of cytokines such as IL-12, led to better understandings regarding how myeloid cells evolved to be the decision makers for T cell differentiation in immunity. Previously, he was director of the Immunology Program of the Division of Biology and Biomedical Sciences. He also is the lead author of the widely respected and comprehensive textbook, “Janeway’s Immunobiology.” He is the recipient of numerous prestigeous awards including William B. Coley Award, the Juvenile Diabetes Foundation’s Career Development Award and of the School of Medicine’s Distinguished Investigator Award.
Hai Qi
Hai Qi
Tsinghua University, China
Dr. Hai Qi is a Professor of School of Medicine, Tsinghua University. Dr. Qi’s research focuses on T-B cell interactions involved in germinal center development, particularly the important roles of signaling lymphocytic activation molecule (SLAM)-associated protein (SAP) and ICOS-mediated costimulatory function.
Feng Shao
Feng Shao
National Institute of Biological Sciences, Member of CAS, China
Dr. Feng Shao is an investigator and deputy director at National Institute of Biological Sciences (NIBS), Beijing, China. He was a chemistry undergraduate of Peking University and obtained his PhD from University of Michigan in 2003. Dr. Shao’s research spans from bacterial pathogenesis to innate immunity and to pyroptotic cell death. His group has identified several cytosolic pattern recognition receptors, including the NAIPs for bacterial flagellin and Pyrin for bacterial Rho-modifying toxins in the caspase-1 inflammasome pathway as well as caspase-11/4/5 for cytosolic LPS. He has also identified Gasdermin-D (GSDMD) whose cleavage by caspase-1/4/5/11 determines pyroptosis, playing important roles in innate defense and sepsis. Dr. Shao’s research further establishes a Gasdermin family of pyroptotic pore-forming factors, thereby re-defining pyroptosis as Gasdermin-mediated programmed necrosis. Among the family, Gasdermin-E (GSDME) is activated by caspase-3, which has important contributions to the adverse effect of chemotherapy drugs. Dr. Shao‘s work has been well recognized by numerous prestigious awards including the HHMI International Early Career Award. Dr. Shao is an elected member of the Chinese Academy of Science, an associate member of European Molecular Biology Organization (EMBO), and a fellow of American Academy of Microbiology.
Shu Hongbing
Shu Hongbing
Wuhan University, Member of the Chinese Academy of Science
Dr. Shu Hongbing is a member of Chinese Academy of Sciences and a Chinese cytologist and immunologist. He is a prefessor and currently Vice President of Wuhan University, China. Dr. Shu is best known for his work on cell signal transduction related to immunity. He discovered several molecules including VISA (virus-induced signaling adaptor) and MITA involved in antiviral interferon signaling.
Louis Staudt
Louis Staudt
NIH, National Cancer Institute, Member of the National Academy of Sciences of USA
Dr. Louis Staudt is a member of the National Academy of Sciences of USA, Co-Chief, Lymphoid Malignancies Branch, Director, Center for Cancer Research, National Cancer Institute, and Senior Investigator, Head, Molecular Biology of Lymphoid Malignancies Section, National Institutes of Health. Dr. Staudt pioneered the use of gene expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy. He defined molecular subtypes of lymphoma that were previously unrecognized but are now viewed as distinct diseases that arise from different stages of B cell differentiation. To develop new treatments for lymphoid malignancies, Dr. Staudt’s laboratory uses various high-throughput approaches, including cancer gene resequencing, RNAi/CRISPR-based genetic screens, and combinatorial small molecule screens. The laboratory also conducts genomic investigations within therapeutic trials of targeted agents in lymphoma to define mechanisms of response and resistance.
Zhigang Tian
Zhigang Tian
University of Science and Technology of China
Dr. Zhigang Tian is Professor and Director, Institute of Immunology and Dean, School of Life Scinces, University of Science & Technology of China. He is current President of Chinese Society for Immunology. Dr. Tian’s research focuses on NK cells, liver immunology and application of immune cell therapy in major diseases (cancer, infection and autoimmunity).
Li Wu
Li Wu
Tsinghua University, China
Dr. Li Wu is Professor and Vice Dean of School of Medicine and Professor of School of Life Sciences at Tsinghua University. She is also a Professor of Chinese “Thousand Talents Program”. Dr. Wu’s research focuses on development and function of dendritic cells in the immune system.
Registration
Essential information
Payment
Traffic information
Booking information

The Conference Accommodation and Hotel Information



The conference will be held at Zhonggeng Jeurong Hotel, Fuzhou, China (Provisional). For registered participants, the conference organizers will help to arrange the accommodation, but not cover expenses.

The hotel address is 203 South Jiangbin Boulevard, Cangshan District, Fuzhou, Fujian Province 350026, China.

Hotel reservation price:

 

Room Types

Room Rate/Day

(Single or Double Occupancy)

Deluxe Room (One king size bed)

450/Room

Deluxe Room (Two twin size beds)

450/Room

Suite

550/Suit

Executive Suite

1100/Suit

 

For reservation:

 

Please fill in the detail information when you sign up for registration.

(Submit abstracts after login)
Sign in
Complete personal information
Essential information
Payment
Traffic information
Booking information

The Conference Accommodation and Hotel Information



The conference will be held at Zhonggeng Jeurong Hotel, Fuzhou, China (Provisional). For registered participants, the conference organizers will help to arrange the accommodation, but not cover expenses.

The hotel address is 203 South Jiangbin Boulevard, Cangshan District, Fuzhou, Fujian Province 350026, China.

Hotel reservation price:

 

Room Types

Room Rate/Day

(Single or Double Occupancy)

Deluxe Room (One king size bed)

450/Room

Deluxe Room (Two twin size beds)

450/Room

Suite

550/Suit

Executive Suite

1100/Suit

 

For reservation:

 

Please fill in the detail information when you sign up for registration.

Scan the code to join the WeChat discussion group
Please scanning QR code to join the conference WeChat group.
Organizer:
Biomedical Research Center of South China, Fujian Normal University
Fujian Key Laboratory of Innate Immune Biology
Co-organizer:
Science and Technology Association of Fujian Normal University
College of Life Sciences, Fujian Normal University